• By ICR Secretariat
• Posted Wednesday, June 15, 2022

Regeneron's cholesterol drug war heats up with lawsuit over Amgen's 'illegal' bundling scheme

https://www.fiercepharma.com/pharma/regenerons-cholesterol-drug-war-heats-antitrust-lawsuit-over-amgens-bundling-scheme

Since their PCSK9 drugs to lower bad cholesterol won FDA approvals a month apart in the summer of 2015, Amgen and Regeneron have waged a war for supremacy in the market—with the California-based drugmaker a decided winner.